IQV Stock Analysis
NYQ · Healthcare · Diagnostics & Research
$270.37
-4.65 (-1.69%)
IQV Interactive Price Chart & Trading Signals
IQV Stock Snapshot — Valuation, Risk & Technical Signals
IQV Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$44.50B
P/E Ratio
33.67
Forward P/E
18.70
PEG Ratio
0.98
P/B Ratio
7.21
EPS
$8.03
Dividend Yield
—
52W Range
$154.50 – $277.40
Beta
1.19
Volume
1.1M
ROE
22.8%
Profit Margin
8.1%
Revenue Growth
8.7%
Gross Margin
33.0%
EV/EBITDA
19.29
Analyst Target
$279.56
The trailing price-to-earnings ratio stands at 33.7x. Forward P/E of 18.7x implies earnings expansion expected. Price-to-book is 7.21x. EV/EBITDA sits at 19.29x. Market capitalization is $44.50B. Revenue is growing at 8.7% on a trailing basis. Earnings are compressing at -0.6%. Profit margins are 8.1%. Return on equity is 22.8%. Beta of 1.19 indicates market-average volatility.
Analyst Consensus
Recommendation
Strong Buy
Low Target
$247.00
Mean Target
$279.56
High Target
$329.00
Based on 18 analysts
About IQV
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
IQV Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
General investorWatch out for
Premium valuation, Earnings declineNon-zero inputs
4/5Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.
IQVIA Holdings Inc. (IQV) trades above our multi-model fair value estimate of $111.91 by approximately 58.6%. Trailing P/E: 33.7x. Profitability signals include profit margin of 8.1% and return on equity of 22.8%. Recent growth metrics show revenue growth of 8.7% and earnings growth of -0.6%. Risk profile: beta of 1.19. Consensus: strong_buy.
Valuation, Growth & Risk
Valuation
Overvalued
P/E 33.7x
Price is above what fundamentals suggest.
Growth
Expanding
Rev 8.7%
Revenue is outpacing the market.
Valuation Snapshot
IQVIA Holdings Inc. (IQV) trades above our multi-model fair value estimate of $111.91 by approximately 58.6%. The trailing price-to-earnings ratio stands at 33.7x. Forward P/E of 18.7x suggests earnings compression ahead. Price-to-sales is 2.6x. Price-to-book is 7.2x. EV/EBITDA sits at 19.3x. Market capitalization is $44.50B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 8.7% on a trailing basis. Earnings are compressing at -0.6%. Profit margins are 8.1%. Return on equity is 22.8%. Return on assets is 5.1%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 1.19 indicates market-average volatility. Net debt position is $14.17B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $279.56 implies 3.4% upside. Target range spans $247.00 to $329.00. 18 analysts cover the stock. Consensus recommendation: strong_buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, and market cap: Yahoo Finance (may be delayed)
- P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
- Analyst estimates: Yahoo Finance (coverage and update times vary)
- Insider transactions: Yahoo Finance (reporting may be delayed)
QuantSoar Model (Derived)
- Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
- Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
IQV Overvalued
IQVIA Holdings Inc. (IQV) trades above our multi-model fair value estimate of $111.91 by approximately 58.6%.
Frequently Asked Questions
ValuationIs IQV stock overvalued right now?
ValuationWhat is IQV fair value based on current fundamentals?
RiskHow risky is IQV compared with other stocks?
GrowthIs IQV still growing?
AnalystWhat do analysts think about IQV?
CatalystWhat could change the investment case for IQV?
Related Stocks
About the Author
Phasakorn Traklang (Peach) — Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.